Prestige Consumer Healthcare Q1 sales fall 6.6%; cuts FY26 revenue and EPS outlook
Prestige Consumer Healthcare reported first-quarter fiscal 2026 revenue of $249.5 million, down 6.6% from $267.1 million a year earlier, citing limited supply of Clear Eyes. It lowered its fiscal 2026 revenue and diluted EPS outlook and agreed to buy Pillar5 Pharma, its Clear Eyes supplier, for CAD 150 million in cash, subject to adjustments. The lower outlook reflects expected eye care supply shortfalls in the first half, and the acquisition is intended to secure supply, though closing depends on conditions and is expected in the third quarter of fiscal 2026.
Key points
- Q1 fiscal 2026 revenue of $249.5 million, down 6.6% from $267.1 million; diluted EPS of $0.95 versus $0.98 a year earlier and $0.90 adjusted
- Fiscal 2026 revenue outlook cut to $1,100 million to $1,115 million from $1,140 million to $1,155 million
- Fiscal 2026 diluted EPS outlook cut to $4.50 to $4.58 from $4.70 to $4.82; free cash flow outlook of $245 million or more unchanged
- Pillar5 Pharma acquisition for CAD 150 million in cash, expected to close in fiscal third quarter 2026 subject to conditions
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.